Olivier Muller
Trends in Coronary and Structural Heart Interventions in Switzerland over the Last 16 Years and Impact of COVID-19: Insights from the National Swiss PCI Survey.
Wagener M, Boeddinghaus J, Gaemperli O, Räber L, Nietlispach F, Meier P, Muller O, Weilenmann D, Jeger R. Trends in Coronary and Structural Heart Interventions in Switzerland over the Last 16 Years and Impact of COVID-19: Insights from the National Swiss PCI Survey. J Clin Med 2022; 11
15.12.2022Trends in Coronary and Structural Heart Interventions in Switzerland over the Last 16 Years and Impact of COVID-19: Insights from the National Swiss PCI Survey.
15.12.2022J Clin Med 2022; 11
Wagener Max, Boeddinghaus Jasper, Gaemperli Oliver, Räber Lorenz, Nietlispach Fabian, Meier Pascal, Muller Olivier, Weilenmann Daniel, Jeger Raban
Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation.
Wenzl F, Kraler S, Ambler G, Weston C, Herzog S, Räber L, Muller O, Camici G, Roffi M, Rickli H, Fox K, de Belder M, Radovanovic D, Deanfield J, Lüscher T. Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation. Lancet 2022; 400:744-756.
29.08.2022Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation.
29.08.2022Lancet 2022; 400:744-756
Wenzl Florian A, Kraler Simon, Ambler Gareth, Weston Clive, Herzog Sereina A, Räber Lorenz, Muller Olivier, Camici Giovanni G, Roffi Marco, Rickli Hans, Fox Keith A A, de Belder Mark, Radovanovic Dragana, Deanfield John, Lüscher Thomas F
Coronary and structural heart interventions in Switzerland 2019
Wagener M, Jeger R, Weilenmann D, Räber L, Nietlispach F, Muller O, Meier P, Gämperli O, Cook S, Twerenbold R, On Behalf Of The Swiss Working Group Interventional Cardiology Of The Swiss Society Of Cardiology. Coronary and structural heart interventions in Switzerland 2019. Swiss Med Wkly 2021; 151:w20495.
11.05.2021Coronary and structural heart interventions in Switzerland 2019
11.05.2021Swiss Med Wkly 2021; 151:w20495
Wagener Max, Jeger Raban, Weilenmann Daniel, Räber Lorenz, Nietlispach Fabian, Muller Olivier, Meier Pascal, Gämperli Oliver, Cook Stéphane, Twerenbold Raphael, On Behalf Of The Swiss Working Group Interventional Cardiology Of The Swiss Society Of Cardiology
Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial
Iglesias J, Windecker S, Valgimigli M, Heg D, Kaiser C, Weilenmann D, Kurz D, Roffi M, Losdat S, Muller O, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. Int J Cardiol 2021; 334:37-41.
20.04.2021Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial
20.04.2021Int J Cardiol 2021; 334:37-41
Iglesias Juan F, Windecker Stephan, Valgimigli Marco, Heg Dik, Kaiser Christoph, Weilenmann Daniel, Kurz David J, Roffi Marco, Losdat Sylvain, Muller Olivier, Pilgrim Thomas
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial
Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwe S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. Cardiovasc Revasc Med 2021; 34:3-10.
25.02.2021Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial
25.02.2021Cardiovasc Revasc Med 2021; 34:3-10
Iglesias Juan F, Windecker Stephan, Jüni Peter, Valgimigli Marco, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Brinkert Miriam, Muller Olivier, Tüller David, Degrauwe Sophie, Roffi Marco, Heg Dik, Pilgrim Thomas
Temporal trends in cardiovascular risk factors prevalence in patients with myocardial infarction
Cimci M, Witassek F, Radovanovic D, Rickli H, Pedrazzini G, Erne P, Muller O, Eberli F, Roffi M. Temporal trends in cardiovascular risk factors prevalence in patients with myocardial infarction. Eur J Clin Invest 2020:e13466.
30.11.2020Temporal trends in cardiovascular risk factors prevalence in patients with myocardial infarction
30.11.2020Eur J Clin Invest 2020:e13466
Cimci Murat, Witassek Fabienne, Radovanovic Dragana, Rickli Hans, Pedrazzini Giovanni B, Erne Paul, Muller Olivier, Eberli Franz R, Roffi Marco
Impact of cardiac rehabilitation participation on patient-reported lifestyle changes one year after myocardial infarction
Hermann M, Rickli H, Radovanovic D, Maggiorini M, Roffi M, Muller O, Eberli F, Erne P, Witassek F, AMIS Plus Investigators. Impact of cardiac rehabilitation participation on patient-reported lifestyle changes one year after myocardial infarction. Eur J Prev Cardiol 2019:2047487319895429.
16.12.2019Impact of cardiac rehabilitation participation on patient-reported lifestyle changes one year after myocardial infarction
16.12.2019Eur J Prev Cardiol 2019:2047487319895429
Hermann Matthias, Rickli Hans, Radovanovic Dragana, Maggiorini Marco, Roffi Marco, Muller Olivier, Eberli Franz, Erne Paul, Witassek Fabienne, AMIS Plus Investigators
Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents
Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. J Am Heart Assoc 2019; 8:e013607.
07.11.2019Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents
07.11.2019J Am Heart Assoc 2019; 8:e013607
Iglesias Juan F, Windecker Stephan, Jüni Peter, Valgimigli Marco, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Moarof Igal, Muller Olivier, Rigamonti Fabio, Lanz Jonas, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
Iglesias J, Windecker S, Jüni P, Zwahlen M, Odutayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019; 394:1243-1253.
02.09.2019Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
02.09.2019Lancet 2019; 394:1243-1253
Iglesias Juan F, Windecker Stephan, Jüni Peter, Zwahlen Marcel, Odutayo Ayodele, Valgimigli Marco, Eeckhout Eric, Losdat Sylvain, Stortecky Stefan, Tapponnier Maxime, Kaiser Christoph, Weilenmann Daniel, Moarof Igal, Kurz David J, Roffi Marco, Heg Dik, Muller Olivier, Pilgrim Thomas
Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial
Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. Circ Cardiovasc Interv 2019; 12:e008024.
06.08.2019Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial
06.08.2019Circ Cardiovasc Interv 2019; 12:e008024
Iglesias Juan F, Windecker Stephan, Jüni Peter, Häner Jonas, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Moarof Igal, Muller Olivier, Noble Stéphane, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial
Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet 2018; 392:737-746.
28.08.2018Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial
28.08.2018Lancet 2018; 392:737-746
Pilgrim Thomas, Jüni Peter, Eberli Franz R, Hunziker Lukas, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Siontis George C M, Moarof Igal, Muller Olivier, Tüller David, Roffi Marco, Heg Dik, Piccolo Raffaele, Windecker Stephan
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial
Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuilliomenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention 2018; 14:692-699.
20.08.2018A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial
20.08.2018EuroIntervention 2018; 14:692-699
Iglesias Juan F, Windecker Stephan, Jüni Peter, Eeckhout Eric, Valgimigli Marco, Heg Dik, Tapponnier Maxime, Kaiser Christoph, Weilenmann Daniel, Vuilliomenet André, Kurz David J, Roffi Marco, Zaugg Serge, Muller Olivier, Pilgrim Thomas
Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention
Hugelshofer S, Windecker S, Masci P, Muller O, Degrauwe S, Erne P, Radovanovic D, Rickli H, Pedrazzini G, Pilgrim T, Eberli F, Witassek F, Roffi M, Iglesias J. Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention. Am Heart J 2018; 204:34-42.
10.07.2018Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention
10.07.2018Am Heart J 2018; 204:34-42
Hugelshofer Sarah, Windecker Stephan, Masci Pier Giorgio, Muller Olivier, Degrauwe Sophie, Erne Paul, Radovanovic Dragana, Rickli Hans, Pedrazzini Giovanni, Pilgrim Thomas, Eberli Franz R, Witassek Fabienne, Roffi Marco, Iglesias Juan F
Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Fournier S, Iglesias J, Eeckhout E, Windecker S, Masci P, Degrauwe S, Zuffi A, Fesselet R, Noble S, Cook S, Erne P, Radovanovic D, Rickli H, Eberli F, Pilgrim T, Roffi M, Benedetto U, Muller O, on behalf on the AMIS Plus Investigators. Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Clin Res Cardiol 2017
08.12.2017Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
08.12.2017Clin Res Cardiol 2017
Fournier Stephane, Iglesias Juan F, Eeckhout Eric, Windecker Stephan, Masci PierGiorgio, Degrauwe Sophie, Zuffi Andrea, Fesselet Rachel, Noble Stéphane, Cook Stéphane, Erne Paul, Radovanovic Dragana, Rickli Hans, Eberli Franz R, Pilgrim Thomas, Roffi Marco, Benedetto Umberto, Muller Olivier, on behalf on the AMIS Plus Investigators
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction
Pilgrim T, Jüni P, Wenaweser P, Blöchlinger S, Nietlispach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. EuroIntervention 2015; 11
23.12.2015Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction
23.12.2015EuroIntervention 2015; 11
Pilgrim Thomas, Jüni Peter, Wenaweser Peter, Blöchlinger Stefan, Nietlispach Fabian, Rigamonti Fabio, Taniwaki Masanori, Khattab Ahmed A, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Muller Olivier, Vuilliomenet André, Tüller David, Roffi Marco, Heg Dik, Piccolo Raffaele, Windecker Stephan
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial
Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. Circ Cardiovasc Interv 2015; 8
01.06.2015Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial
01.06.2015Circ Cardiovasc Interv 2015; 8
Franzone Anna, Jüni Peter, Wenaweser Peter, Stortecky Stefan, Räber Lorenz, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Muller Olivier, Vuilliomenet André, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas, Windecker Stephan
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014; 384:2111-22.
01.09.2014Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
01.09.2014Lancet 2014; 384:2111-22
Pilgrim Thomas, Jüni Peter, Wenaweser Peter, Eberli Franz R, Noble Stéphane, Moschovitis Aris, Fahrni Therese, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Vuilliomenet André, Muller Olivier, Tüller David, Roffi Marco, Heg Dik, Windecker Stephan
Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial
Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. Am Heart J 2014; 168:256-61.
06.06.2014Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial
06.06.2014Am Heart J 2014; 168:256-61
Pilgrim Thomas, Jüni Peter, Heg Dik, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Vuilliomenet André, Muller Olivier, Tüller David, Roffi Marco, Windecker Stephan
Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus
Wuerzner G, Pechère-Bertschi A, Baumgartner I, Jacob A, Burnier M, Qanadli S, Swiss Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Angiology, Sticherling C, Kaiser C, Waeber B, Muller O, Erne P, Cook S, Sudano I, Lüscher T, Noll G, Kaufmann U, Rickli H, Swiss Society of Cardiovascular and Interventional Radiology. Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus. Swiss Med Wkly 2014; 144:w13913.
20.03.2014Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus
20.03.2014Swiss Med Wkly 2014; 144:w13913
Wuerzner Gregoire, Pechère-Bertschi Antoinette, Baumgartner Iris, Jacob Augustinus L, Burnier Michel, Qanadli Salah D, Swiss Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Angiology, Sticherling Christian, Kaiser Christophe, Waeber Bernard, Muller Olivier, Erne Paul, Cook Stéphane, Sudano Isabella, Lüscher Thomas F, Noll Georg, Kaufmann Urs, Rickli Hans, Swiss Society of Cardiovascular and Interventional Radiology